Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 450

1.

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.

White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG.

Eur Heart J. 2019 May 23. pii: ehz299. doi: 10.1093/eurheartj/ehz299. [Epub ahead of print]

PMID:
31121022
2.

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.

Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators.

Circulation. 2019 May 23. doi: 10.1161/CIRCULATIONAHA.118.038840. [Epub ahead of print]

PMID:
31117810
3.

Stroke in Patients With Peripheral Artery Disease.

Kolls BJ, Sapp S, Rockhold FW, Jordan JD, Dombrowski KE, Fowkes FGR, Mahaffey KW, Berger JS, Katona BG, Blomster JI, Norgren L, Abramson BL, Leiva-Pons JL, Prieto JC, Sokurenko G, Hiatt WR, Jones WS, Patel MR.

Stroke. 2019 May 16:STROKEAHA118023534. doi: 10.1161/STROKEAHA.118.023534. [Epub ahead of print]

PMID:
31092165
4.

Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry.

Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW.

J Am Heart Assoc. 2019 May 7;8(9):e011205. doi: 10.1161/JAHA.118.011205.

5.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744. [Epub ahead of print]

PMID:
30990260
6.

Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation.

Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Chan P, Allen LA, Gersh BJ; ORBIT AF Investigators.

Am Heart J. 2019 May;211:77-89. doi: 10.1016/j.ahj.2019.01.005. Epub 2019 Jan 30.

PMID:
30901602
7.

Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 Mar 17. doi: 10.1161/CIRCULATIONAHA.119.040057. [Epub ahead of print]

PMID:
30882240
8.

Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment.

Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007445. doi: 10.1161/CIRCINTERVENTIONS.118.007445.

PMID:
30871355
9.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B.

Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.

10.

Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry).

Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Chang P, Fonarow GC, Ezekowitz MD, Hylek E, Go AS, Kowey PR, Mahaffey KW, Gersh BJ, Peterson ED.

Am J Cardiol. 2019 May 15;123(10):1628-1636. doi: 10.1016/j.amjcard.2019.02.010. Epub 2019 Feb 23.

PMID:
30846214
11.

Characteristics of Digital Health Studies Registered in ClinicalTrials.gov.

Chen CE, Harrington RA, Desai SA, Mahaffey KW, Turakhia MP.

JAMA Intern Med. 2019 Feb 25. doi: 10.1001/jamainternmed.2018.7235. [Epub ahead of print] No abstract available.

PMID:
30801617
12.

Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration.

Leef GC, Perino AC, Askari M, Fan J, Ho PM, Olivier CB, Longo L, Mahaffey KW, Turakhia MP.

J Pharm Pract. 2019 Feb 21:897190019828270. doi: 10.1177/0897190019828270. [Epub ahead of print]

PMID:
30791808
13.

Canagliflozin review - safety and efficacy profile in patients with T2DM.

Jakher H, Chang TI, Tan M, Mahaffey KW.

Diabetes Metab Syndr Obes. 2019 Feb 1;12:209-215. doi: 10.2147/DMSO.S184437. eCollection 2019. Review.

14.

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators.

N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7.

PMID:
30730782
15.

Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.

Gutierrez JA, Mulder H, Jones WS, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Held P, Katona BG, Mahaffey KW, Norgren L, Hiatt WR, Patel MR.

JAMA Netw Open. 2018 Nov 2;1(7):e185239. doi: 10.1001/jamanetworkopen.2018.5239.

16.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.

Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B.

Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.

17.

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Fanaroff AC, Clare R, Pieper KS, Mahaffey KW, Melloni C, Green JB, Alexander JH, Jones WS, Harrison RW, Mehta RH, Povsic TJ, Moreira HG, Al-Khatib SM, Roe MT, Kong DF, Mathews R, Tricoci P, Holman RR, Wallentin L, Held C, Califf RM, Alexander KP, Lopes RD.

Circulation. 2019 Feb 12;139(7):863-873. doi: 10.1161/CIRCULATIONAHA.118.037202.

PMID:
30586739
18.

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.

Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR; EUCLID Trial Executive Committee and Investigators.

J Am Coll Cardiol. 2018 Dec 25;72(25):3274-3284. doi: 10.1016/j.jacc.2018.09.078.

PMID:
30573030
19.

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.

Held C, White HD, Stewart RAH, Davies R, Sampson S, Chiswell K, Silverstein A, Lopes RD, Heldestad U, Budaj A, Mahaffey KW, Wallentin L; STABILITY Investigators.

Am Heart J. 2019 Feb;208:65-73. doi: 10.1016/j.ahj.2018.10.010. Epub 2018 Nov 7.

20.

Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.

Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm C, Price MJ, Prats J, Elkin S, Deliargyris EN, White HD, Menozzi A, Harrington RA, Bhatt DL; MPH on Behalf of the CHAMPION PHOENIX Investigators.

Int J Cardiol. 2019 Mar 1;278:217-222. doi: 10.1016/j.ijcard.2018.11.114. Epub 2018 Nov 23.

Supplemental Content

Loading ...
Support Center